Objective: To discover, by using metabolomics, novel candidate biomarkers for stroke recurrence (SR) with a higher prediction power than present ones.
New techniques such as metabolomics provide the opportunity to identify new biomarkers. 13 This has been applied in stroke research 14, 15 but no description of SR after early recovery such as that present in TIA patients appeared.
The aim of the present study was to perform a metabolomic analysis of plasma from a cohort of TIA patients in order to find (1) new candidate biomarkers associated with SR, (2) temporal patterns of recurrence, and (3) the potential impact of LAA in the plasma metabolomic profile. Results were then validated in an independent cohort, thus ensuring robustness of the resulting candidate biomarker.
METHODS Standard protocol approvals, registrations, and patient consents. The study was approved by the ethics committee of the Arnau de Vilanova University Hospital. Patient consent was obtained from all the donors.
Subjects. We prospectively recruited consecutive patients with transient neurologic deficit who were attended by a neurologist in the emergency department during the first 24 hours after the onset of symptoms (REGITELL registry). 16 These patients were aleatorized into 2 cohorts (e-Methods on the Neurology ® Web site at Neurology. org). TIA was defined as acute onset of focal cerebral or monocular symptoms lasting ,24 hours attributable to brain ischemia. The number of TIA patients attended in our hospital during the study period (January 2008 to January 2012) determined the sample size. Risk factor profile; clinical characteristics; age, blood pressure, clinical features, duration of symptoms, and diabetes score (ABCD2) 17 ; ultrasound; and neuroimaging protocols were recorded as described in e-Methods.
Follow-up and clinical endpoints. Endpoint event was SR. A stroke physician performed clinical visits during the follow-up at 7 days, 3 months, and every 6 months. Imaging data were required to confirm brain ischemia in all SR patients considered. Recurrence of a TIA was not considered an endpoint.
Metabolomic analysis. For nontargeted metabolomics analysis, metabolites were extracted from plasma samples and analyzed using liquid chromatography coupled to mass spectrometry as described in e-Methods.
Statistical analysis. Statistics calculations were performed using SPSS software for Macintosh, version 20 (SPSS, Chicago, IL), R software, or the Stata 11 statistics package (StataCorp, College Station, TX). Further information for tests used appears in e-Methods.
RESULTS Clinical characteristics of the study population. Table 1 shows baseline characteristics of both cohorts, comprising 293 patients. As confounders for the metabolomic analyses, we excluded significant differences in characteristics for vascular risk factors, clinical symptoms, ABCD2 score, etiologic subtypes, or discharge treatments between the 2 cohorts. Previous anticoagulation tended to be more frequent among those patients from the first cohort. The cohorts did not differ significantly in terms of SR.
A total of 35 patients had SR. Two patients died due to recurrent ischemia. In the univariate analysis (table 2) , only LAA and ABCD2 score were associated with SR. Clopidogrel and anticoagulation at discharge were associated with SR.
Subsequent stroke risk exhibits a specific metabolomic profile. Untargeted metabolomic analysis in cohort 1 indicated plasma biomarker potentially indicating future SR. Molecular features detected (present in at least 50% of samples in the same group) are represented in the heat map ( figure 1B ). TIA patients with SR had a specific metabolomic signature, as shown by partial least squares discriminant analysis (PLS-DA) ( figure 1C ), reaching an accuracy ranging from 66% (in positive ionization, specificity 5 0.63, sensitivity 5 0.95) to 73% (in negative ionization, specificity 5 0.68, sensitivity 5 1). The individual importance of molecules in the model is presented in the supplemental data (dataset 1).
Univariate statistics revealed that 94 ions differentiated SR from non-SR patients (p , 0.05) (dataset 2, supplemental data). By using orthogonal approaches (exact mass, isotope distribution, tandem mass spectrometry [MS/MS], and retention time database), 6 molecules were identified: 1-monopalmitin, dodecanoic acid, meso-erythritol, threonate, and lysophosphatidylcholine (LysoPC[16:0]) downregulated and myristoyl-ethanolamine upregulated (p , 0.05) in SR patients. After pathway analysis, these molecules clustered into free fatty acid metabolism, energy metabolism, and solute carrier (SLC)-mediated transmembrane transport pathways (dataset 3, supplemental data).
Temporal patterns of stroke recurrence define specific metabolomic profiles. The results ( figure 1D) show that PLS-DA of metabolomic profiles has a high accuracy in differentiating early SR from later SR groups (dataset 1). A total of 325 ions differentiated the groups by analysis of variance (p , 0.05, dataset 2). These molecules (14 metabolites identified among all the differential ions), indicating early recurrence, clustered into different metabolic pathways with 13 common between recurrence and temporal patterns of recurrence, including fatty acid metabolism (biosynthesis, transport, and receptors) and regulation of insulin secretion (table e-1, dataset 3).
Patients with LAA have a specific metabolomic pattern.
We focused on LAA etiology because of its importance as a SR predictor. [4] [5] [6] We evaluated metabolomic profiles of patients with symptomatic carotid or intracranial stenosis of at least 50%. The results (figure 1E) revealed that metabolomic profiles are able to offer a high accuracy predicting presence of LAA (PLS-DA accuracy 91%-98%, positive: specificity 5 0.79, sensitivity 5 1; negative: specificity 5 0.86, sensitivity 5 1; dataset 1). A total of 73 metabolites were significantly different (Student t test) between LAA and non-LAA (dataset 2), with the resulting molecules identified after MS/MS analyses being androsterone, stearic acid, ascorbic acid, and LysoPC(22:6), all upregulated in patients with LAA (p , 0.05). Results validation using an independent cohort. The multivariate analysis of an independent cohort (cohort 2) confirmed (1) metabolomic signature of SR; (2) metabolomics-based differentiation of SR temporal patterns; and (3) differences between LAA and non-LAA (figure e-1, A-C). Common pathways affected by temporal patterns of recurrence between the 2 independent cohorts included biosynthesis of unsaturated fatty acids and SLC-transport-related pathways (dataset 3). In both cohorts, LysoPC(16:0) was significantly decreased in early SR patients ( figure 2, A and B) , whereas LysoPC(22:6) was upregulated in LAA patients (figure 2, C and D).
Predictive potential of SR biomarkers described. In order to define the capacity of these potential biomarkers, receiver operating characteristic (ROC) curves were performed using metabolites present in at least 70% of the samples in the same group (SR and non-SR), pooling both cohorts, due to low number of SR. The results ( figure 2E, When only early SR was considered, an unidentified metabolite (figure e-1D) arose as a potential biomarker also increasing the predictive power of ABCD2 or LAA score (from 62%-67% to 71%). DISCUSSION The results demonstrate the feasibility and utility of the metabolomic approach to reveal potential biomarkers for SR after TIA, and for its most frequent independent predictor, LAA. We identified candidate biomarkers for both SR prediction and LAA detection, both belonging to LysoPC family. These biomarkers arose after analysis in 2 independent cohorts (n 5 131; n 5 162), reinforcing potential study generalizability.
We initially identified that a small set of metabolites are different between SR and no SR. Considering only this small set of metabolites, we reach an accuracy of .60% in segregating these 2 populations, suggesting that a combination of relatively low number of metabolites is, at least, as good as previous Table 2 Continued clinical, imaging, or etiologic variables in predicting SR. Future work devoted to identify these and new metabolites will help to increase the accuracy of the test and ultimately develop a more scalable tool for patients to assess their risk of SR. Low plasma levels of LysoPC(16:0) arose as a potential predictor of recurrence, especially in patients with early SR. This compound is one of the products of Lp-PLA2 whose levels have been shown to be increased in adverse prognosis after stroke. 11, 18 Moreover, high levels of Lp-PLA2 and LysoPC (16:0) are associated with symptomatic carotid plaques. 19 LysoPC(16:0) by itself increases on brain after stroke 20, 21 where it mediates phagocyte recruiting 22 that can contribute to ischemic brain injury 23 and also produces neuroinflammatory effects when applied on CNS. 24 All these results could pinpoint a beneficial effect of reduced LysoPC(16:0) levels that argue against our claim that it marks an early SR risk, but although high levels of plaque LysoPC(16:0) are correlated with high plasma and plaque levels of Lp-PLA2, plasma LysoPC(16:0) levels are not. 25 It has been demonstrated that plasma LysoPC(16:0) can inhibit Lp-PLA2 activity both in vitro and in vivo, 26 thereby suppressing their neuroinflammative properties. 27 Apart from suppressing Lp-PLA2 activity, plasmatic LysoPC(16:0) is neuroprotective on brain ischemia models, 28 mainly through activation of TREK-1 potassium channels. 29 Finally, it is known that LysoPC(16:0) is a potent inducer of superoxide ion production in endothelial cells 30 and controlled levels of superoxide serve as angiogenic factors in ischemic angiogenesis. 31 Due to all these neuroprotective properties, decreased plasma levels of LysoPC (16:0) could contribute to an early SR risk. Nonetheless, when we evaluated potential risk models accounting LysoPC(16:0), it did not add a significant value over the clinical parameters explained by ABCD2 and LAA presence. This fits with the fact that ABCD2 and LAA are closely related to pathophysiologic events previously invoked in the homeostasis of LysoPC16:0 (enumerated above). The potential implication of LysoPC metabolism in SR was further reinforced by the finding of LysoPC(20:4) as a potential biomarker of SR based on ROC curves of aggregated cohorts. Interestingly, after the use of NRI, IDI, and Hosmer-Lemeshow test, the statistics indicated that LysoPC(20:4) significantly improves prediction capacities of combined ABCD2 and LAA scores. These data are in line with other LysoPC species containing fatty acids of 20C length, decreased in plasma in experimental models of ischemia. 32 This molecule exhibits antiinflammatory potential in preclinical models, 33 reinforcing the role of inflammation in ischemic recurrence or tolerance. Interestingly, as with other biomarkers, 8, 11 LysoPCs exhibit the potential to increase the prognostic accuracy of clinical scores or LAA and could help management decisions, a hypothesis to be validated in further studies.
Finally, we identified LysoPC(22:6) as a potential LAA biomarker. As far as we know, no previous studies have focused on the role of LysoPC(22:6) on carotid plaque formation or stability but increased levels in symptomatic LAA patients could point to a role in this processes. N-3 polyunsaturated fatty acids, such as docosahexaenoic acid (22:6) , are precursors of molecules implicated in the resolving phase of inflammation. Therefore, the higher levels of LysoPC (22:6) in LAA could be an indicator of reactive response to inflammation associated with atheroma plaque development.
As limitations of the present work, we recognize the significant heterogeneity and small sample size for SR among the studied population. The metabolome, even in healthy phenotypically similar patients, exhibits a considerable variance across the time. [34] [35] [36] Furthermore, the samples were taken in the emergency Table 3 Predictive accuracy of clinical variables and biomarkers derived from the metabolomic study for recurrent stroke at the 7-day, 90-day, and room, without controlling for previous food intake. Nevertheless, the results provided were strengthened by the use of 2 independent cohorts. Further, we are not able to identify an important percentage of metabolites present in samples, due to the major bottleneck in metabolomics: the lack of comprehensive metabolite databases. 37 However, the use of databases repositories with accurate mass and retention time in reproducible chromatographic systems will ease the future identification of these metabolites.
In the future, metabolomics could be useful to detect new biomarkers related to other interesting phenomena related to transient ischemia, the ischemic tolerance. Nonlacunar ischemic stroke patients with recent previous episodes of TIA have a favorable outcome, suggesting a neuroprotective effect of TIA by inducing a phenomenon of precondition ischemia. 38 
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